Literature DB >> 18025794

Cord blood KL-6, a specific lung injury marker, correlates with the subsequent development and severity of atypical bronchopulmonary dysplasia.

Do-Hyun Kim1, Han-Suk Kim, So-Yeon Shim, Jin-A Lee, Chang Won Choi, Ee-Kyung Kim, Beyong Il Kim, Jung-Hwan Choi.   

Abstract

BACKGROUND: A considerable number of preterm infants may have been exposed to inflammation in utero and may be born with an inflamed lung.
OBJECTIVES: To determine the impact of antenatal lung injury and inflammatory response on the pathogenesis of bronchopulmonary dysplasia (BPD) according to its clinical pattern, using KL-6 (as a lung injury marker) and C-reactive protein (CRP) (as a marker of inflammatory response).
METHODS: In this case-control study, a total of 74 infants (<32 weeks of gestation) including BPD with minimal early lung disease ('atypical'; 21 infants), BPD with significant early lung disease ('classic'; 29 infants) and the non-BPD (24 infants) groups underwent KL-6 and CRP in cord blood determinations.
RESULTS: The cord plasma KL-6 levels were significantly higher in the atypical and the total BPD groups than in the non-BPD group (median = 60.9 vs. 34.5 U/ml, p = 0.031; 43.5 vs. 34.5 U/ml, p = 0.02). However, the cord plasma CRP levels were not significantly different among the study groups. The cord plasma KL-6 levels in patients with atypical BPD were significantly higher in infants with moderate or severe BPD than in infants with mild BPD (median = 88.3 vs. 41.5 U/ml, p = 0.041) and were found to be significantly correlated with the duration of oxygen therapy (r = 0.502, p = 0.024).
CONCLUSIONS: The present study shows that cord plasma KL-6, a specific lung injury marker, is increased and objectively reflects disease severity in atypical BPD. (c)2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025794     DOI: 10.1159/000111100

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  7 in total

1.  Correlation of serum KL-6 and CC16 levels with neurodevelopmental outcome in premature infants at 12 months corrected age.

Authors:  Zhiqun Zhang; Hui Lu; Yunxia Zhu; Junhua Xiang; Xianmei Huang
Journal:  Sci Rep       Date:  2015-01-29       Impact factor: 4.379

2.  Histologic Chorioamnionitis, Amniotic Fluid Interleukin 6, Krebs von den Lungen 6, and Transforming Growth Factor β1 for the Development of Neonatal Bronchopulmonary Dysplasia.

Authors:  Hisako Matsumura; Hiroyuki Ichiba; Satoshi Ohnishi; Mika Saito; Haruo Shintaku
Journal:  Jpn Clin Med       Date:  2017-03-07

3.  Association of Chorioamnionitis With Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review, Meta-analysis, and Metaregression.

Authors:  Eduardo Villamor-Martinez; María Álvarez-Fuente; Amro M T Ghazi; Pieter Degraeuwe; Luc J I Zimmermann; Boris W Kramer; Eduardo Villamor
Journal:  JAMA Netw Open       Date:  2019-11-01

4.  A comparison of KL-6 and Clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants.

Authors:  Keyi Wang; Xianmei Huang; Hui Lu; Zhiqun Zhang
Journal:  Dis Markers       Date:  2014-08-27       Impact factor: 3.434

Review 5.  BPD Following Preterm Birth: A Model for Chronic Lung Disease and a Substrate for ARDS in Childhood.

Authors:  Anita Bhandari; Christopher Carroll; Vineet Bhandari
Journal:  Front Pediatr       Date:  2016-06-15       Impact factor: 3.418

Review 6.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

7.  Predicting the severity of acute bronchiolitis in infants: should we use a clinical score or a biomarker?

Authors:  Flore Amat; Cécile Henquell; Matthieu Verdan; Laurence Roszyk; Aurélien Mulliez; André Labbé
Journal:  J Med Virol       Date:  2013-12-27       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.